Former Lawyer Went From $50K To $5.3M Trading Options
Slaving away for 70 hrs a week as a lawyer in Chicago, I was miserable.

I ran into guys who worked the trading floor at the local exchange. I began trading the same way they did. I started out with $50K (much more than I needed, actually).

I grew my $50K into $5.3M
I'll show you how I did it here.
Albert P L Stroucken, insider at Baxter International

Albert P L Stroucken Insider Information

Albert P.L. Stroucken has served as a director of Baxter since 2004 and was appointed lead director in February 2021.

Stroucken is former executive chairman of the board of directors of Owens-Illinois, Inc., where he also served as chairman, president, and chief executive officer from 2006 through 2015. From 1998 to 2006, Stroucken served as president and chief executive officer of H.B. Fuller Company, a manufacturer of adhesives, sealants, coatings, paints, and other specialty chemicals. He served as chairman of H.B. Fuller Company from 1999 to 2006.

From 1997 to 1998, he was general manager of the inorganics division of Bayer AG. From 1992 to 1997, Stroucken was executive vice president and president of the industrial chemicals division of Bayer Corporation. He previously served as director of Baxalta and of Shire (before it was acquired by Takeda Pharmaceutical in 2019).

What is Albert P L Stroucken's net worth?

The estimated net worth of Albert P L Stroucken is at least $1.80 million as of April 5th, 2022. Stroucken owns 27,629 shares of Baxter International stock worth more than $1,802,792 as of June 29th. This net worth estimate does not reflect any other investments that Stroucken may own. Learn More about Albert P L Stroucken's net worth.

How do I contact Albert P L Stroucken?

The corporate mailing address for Stroucken and other Baxter International executives is One Baxter Parkway DF2-1W, Deerfield IL, 60015. Baxter International can also be reached via phone at (224) 948-2000 and via email at [email protected] Learn More on Albert P L Stroucken's contact information.

Has Albert P L Stroucken been buying or selling shares of Baxter International?

In the last ninety days, Albert P L Stroucken has sold $305,600.40 in Baxter International stock. 0 shares of the firm's stock in a transaction on Wednesday, June 29th. Learn More on Albert P L Stroucken's trading history.

Who are Baxter International's active insiders?

Baxter International's insider roster includes Giuseppe Accogli (SVP), John Forsyth (Director), Andrew Frye (SVP), James Gavin, III (Director), Jeanne Mason (SVP), Brian Stevens (CAO), and Albert Stroucken (Director). Learn More on Baxter International's active insiders.

Are insiders buying or selling shares of Baxter International?

In the last year, insiders at the medical instruments supplier sold shares 2 times. They sold a total of 6,520 shares worth more than $519,350.40. The most recent insider tranaction occured on April, 5th when Director Albert P L Stroucken sold 4,020 shares worth more than $305,600.40. Insiders at Baxter International own 0.2 % of the company. Learn More about insider trades at Baxter International.

Information on this page was last updated on 4/5/2022.

Albert P L Stroucken Insider Trading History at Baxter International

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
4/5/2022Sell4,020$76.02$305,600.4027,629View SEC Filing Icon  
4/5/2021Sell4,990$84.56$421,954.4036,886View SEC Filing Icon  
4/1/2020Sell4,320$79.64$344,044.8034,018View SEC Filing Icon  
4/10/2017Sell4,280$52.80$225,984.0025,667View SEC Filing Icon  
See Full Table

Albert P L Stroucken Buying and Selling Activity at Baxter International

This chart shows Albert P L Stroucken's buying and selling at Baxter International by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Baxter International Company Overview

Baxter International logo
Baxter International Inc., through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company offers peritoneal dialysis and hemodialysis, and additional dialysis therapies and services; intravenous therapies, infusion pumps, administration sets, and drug reconstitution devices; remixed and oncology drug platforms, inhaled anesthesia and critical care products and pharmacy compounding services; parenteral nutrition therapies and related products; biological products and medical devices used in surgical procedures for hemostasis, tissue sealing and adhesion prevention; and continuous renal replacement therapies and other organ support therapies focused in the intensive care unit. It also provides connected care solutions, including devices, software, communications, and integration technologies; integrated patient monitoring and diagnostic technologies to help diagnose, treat, and manage a various illness and diseases, including respiratory therapy, cardiology, vision screening, and physical assessment; surgical video technologies, tables, lights, pendants, precision positioning devices and other accessories. In addition, the company offers contracted services to various pharmaceutical and biopharmaceutical companies. Its products are used in hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors' offices, and patients at home under physician supervision. The company sells its products through direct sales force, as well as through independent distributors, drug wholesalers, and specialty pharmacy or other alternate site providers in approximately 100 countries. It has an agreement with Celerity Pharmaceutical, LLC to develop acute care generic injectable premix and oncolytic molecules. Baxter International Inc. was incorporated in 1931 and is headquartered in Deerfield, Illinois.
Read More

Today's Range

Now: $65.25
Low: $65.18
High: $67.10

50 Day Range

MA: $71.61
Low: $63.83
High: $78.56

2 Week Range

Now: $65.25
Low: $63.25
High: $89.70

Volume

2,548,930 shs

Average Volume

3,206,073 shs

Market Capitalization

$32.86 billion

P/E Ratio

31.22

Dividend Yield

1.74%

Beta

0.62
This Stock Could Make Headlines
This stock offers a lot of potential in this bear market.
Get more details right here.